Eprotirome further reduces cholesterol levels in statin-treated patients

From theheart.org, by Michael O’Riordan

Baltimore, MD – Adding the investigational thyroid hormone analog eprotirome (Karo Bio) to statin therapy in patients with dyslipidemia results in substantially further reductions in LDL cholesterol and other lipid and lipoprotein levels, a new study shows [1]. The improvements in the atherogenic profile occurred without adversely affecting the heart or skeletal system, two common side effects of thyroid hormone analogs, report investigators.

Continue reading